Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN IN DEXTROSE versus IPRIVASK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN IN DEXTROSE versus IPRIVASK.
ARGATROBAN IN DEXTROSE vs IPRIVASK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Argatroban is a direct thrombin inhibitor that binds reversibly to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, XIII, and protein C, and platelet aggregation.
Direct thrombin inhibitor; binds reversibly to the active site of free and clot-bound thrombin, inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Initial bolus of 350 mcg/kg IV over 3-5 minutes, followed by continuous IV infusion at 25 mcg/kg/min for normal coagulation; titrate to aPTT 1.5-3 times baseline, not exceeding 100 seconds; typical infusion rate 2-10 mcg/kg/min.
Adults: 1 mg/kg intravenously twice daily.
None Documented
None Documented
Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged in hepatic impairment (up to 3.1 hours). Clinically, it corrects within 2–4 hours after infusion cessation.
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; up to 6 hours in severe impairment).
Primarily hepatobiliary (fecal excretion) ~65% as unchanged drug and metabolites; renal excretion ~22% (12% unchanged, 10% as metabolites). Minimal biliary excretion of unchanged drug.
Renal: 70% as unchanged drug; biliary/fecal: 30% (metabolites and unchanged drug).
Category C
Category C
Direct Thrombin Inhibitor
Direct Thrombin Inhibitor